On October 12th, GTH, the leading company in precision medicine on NASDAQ, announced the formal signing of a privatization merger agreement. The privatization transaction is expected to be completed in the first quarter of 2024.
Genetron Health is a leading Chinese cancer precision medicine company dedicated to providing a one-stop molecular diagnostic solution for multiple applications, including cancer diagnosis and monitoring, early screening, and drug development services. The company went public on NASDAQ in June 2020.
The buyer group participating in this privatization transaction includes Zhongjin Kangrui Medical Fund, Wealth Strategy Holding Limited, Wuxi Guolian Group, China International Capital Corporation (Beijing) Investment Fund Management Co., Ltd., and Wuxi Huishan Yingkang Investment Partnership (Limited Partnership).
Llinks, as the legal advisor to Wuxi Huishan Yingkang Investment Partnership (Limited Partnership), assisted in the analysis and recommendations of the transaction structure, reviewed, negotiated, and modified the privatization transaction documents, and actively participated in the project's full-service process from the perspective of government-guided funds, providing professional legal services for Wuxi Huishan Yingkang Investment Partnership (Limited Partnership) in this investment.
Llinks Team:
Partner: Lawrence An
Contractual Partner: Liang Tao
